Scarica l'app Stockscreener
16.41
0.61%
-0.10
Dopo l'orario di chiusura:
16.35
-0.06
-0.37%
Precedente Chiudi:
$16.51
Aprire:
$16.37
Volume 24 ore:
809.10K
Relative Volume:
1.29
Capitalizzazione di mercato:
$880.88M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-54.81%
1M Prestazione:
-58.31%
6M Prestazione:
+64.59%
1 anno Prestazione:
+76.83%
Intervallo 1D:
$15.80
$17.15
Intervallo di 1 settimana:
$13.50
$36.64
Portata 52W:
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Confronta ZBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.41 | 886.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Why Zenas BioPharma Inc. stock is favored by top institutionsJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - PR Newswire
What insider trading reveals about Zenas BioPharma Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
Will Zenas BioPharma Inc. stock benefit from upcoming earnings reportsWeekly Investment Recap & Safe Investment Capital Preservation Plans - ulpravda.ru
Will Zenas BioPharma Inc. stock reach Wall Street targetsRisk Management & Reliable Momentum Entry Alerts - ulpravda.ru
Is Zenas BioPharma Inc. stock a bargain at current levels2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Yahoo Finance UK
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study - sharewise.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas ... - Bluefield Daily Telegraph
Morgan Stanley Downgrades Zenas BioPharma (ZBIO) Rating and Pric - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% Following Analyst Downgrade - MarketBeat
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Canada
Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win - Yahoo Finance
Jefferies lowers Zenas Biopharma stock price target to $48 on trial data - Investing.com Canada
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions? - Yahoo Finance
Zenas BioPharma Stock Pre-Market (-4.0%) : Fallout From Phase 3 Data Disappointment - Trefis
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial, ETPharma - ETPharma.com
Zenas BioPharma’s immune disorder drug meets main goal in late-stage trial - whbl.com
Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results - Investing.com Canada
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Equal Weight" Rating by Morgan Stanley - MarketBeat
Zenas BioPharma Stock Plummets 57% Despite Positive Phase 3 INDIGO Results - Nasdaq
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap DownHere's Why - MarketBeat
Obexelimab’s Strong Phase 3 Data and Differentiated Positioning Underpin Zenas BioPharma Buy Rating and $44 Target - TipRanks
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
Zenas BioPharma Shares Phase III INDIGO Win as Obexelimab Cuts IgG4-RD Flare Risk 56% - MarketBeat
Zenas BioPharma announces positive phase 3 Obexelimab results - MSN
Indigo grills: Street querying Zenas phase III IgG4-RD beat - BioWorld MedTech
Zenas shares crash after top drug misses expectations in immune disease study - BioPharma Dive
Zenas shares plunge on weaker-than-expected data for immune disorder drug - marketscreener.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Zenas posts late-stage trial data for lead asset (ZBIO:NASDAQ) - Seeking Alpha
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - TradingView — Track All Markets
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results - TipRanks
Zenas BioPharma stock falls after Phase 3 trial results By Investing.com - Investing.com Canada
Zenas BioPharma’s obexelimab shows 56% reduction in IgG4-RD flares By Investing.com - Investing.com Canada
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - The Manila Times
Experimental IgG4-related disease drug sharply cuts flare risk in trial - Stock Titan
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A Promising 34.95% Upside in the Biotech Arena - DirectorsTalk Interviews
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus - ts2.tech
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus - ts2.tech
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.4%Here's Why - MarketBeat
Is Zenas BioPharma Inc. stock attractive after correctionCandlestick Pattern Analysis & Small Capital Gains - bollywoodhelpline.com
Zenas BioPharma, Inc (NASDAQ:ZBIO) Drives Innovation in Biologic Science - Kalkine Media
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Non sono disponibili dati finanziari per Zenas Biopharma Inc (ZBIO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):